The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
Abstract
PURPOSE: 5-Aza-2′-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has shown a 50% response rate in a small phase II study in elderly patients with high-risk myelodysplastic syndrome. We performed a second, multicenter phase II study in a larger group of patients to confirm our findings and to study the toxicity of DAC. PATIENTS AND METHODS: Between June 1996 and September 1997, 66 patients (median age, 68 years) from seven centers received DAC 45 mg/m 2/d for 3 days every 6 weeks. For patients in whom a complete response (CR) was reached after two courses, two further cycles were administered as consolidation therapy. In case of a stable disease situation, improvement, or a partial response (PR), a maximum of six cycles was administered. The primary end points were response rate and toxicity. The secondary end points were response duration, survival from the start of therapy, and overall survival. RESULTS: The observed overall response rate was 49%, with a 64% response rate in the patients with an International Prognostic Scoring System (IPSS) high-risk score. The actuarial median response duration was 31 weeks, with a response duration of 39 weeks and 36 weeks for patients who reached a PR or CR, respectively. The actuarial median survival time from the time of diagnosis was 22 months and from the start of therapy was 15 months. For the IPSS high-risk group, the median survival time was 14 months. The median progression-free survival time was 25 weeks. Myelosuppression was rather common, and the treatment-related mortality rate was 7% and was primarily associated with pancytopenia and infection. Significant responses were observed with regard to megakaryopoiesis, with increases in platelet counts having already occurred after one cycle of DAC therapy in the majority of the responding patients. CONCLUSION: We were able to confirm our previous observation that DAC therapy was effective in half of the studied patients with high-risk myelodysplastic syndrome and is especially active in the patients with the worst prognoses. Myelosuppression was the only major adverse effect observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Gehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman, J. G., Jen, J., Merlo, A. U., & Baylin, S. B. (1996) · PubMed · Cited by 571
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
Pinto, A., Attadia, V, Fusco, A., Ferrara, F., Spada, O., & Di Fiore, P. (1984) · Blood · doi:10.1182/blood.v64.4.922.922 · Cited by 175
DNA methylation changes in hematologic malignancies: biologic and clinical implications.
Issa, J. J., Baylin, S. B., & Herman, J. G. (1997) · PubMed · Cited by 153
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
Kantarjian, H., O'Brien, S., Keating, M. J., Beran, M., Estey, E. H., Giralt, S. A., Kornblau, S. M., Rios, M., Vos, D. D., & Talpaz, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400796 · Cited by 130
Stimulation of Hematopoiesis by Amifostine in Patients With Myelodysplastic Syndrome
List, A. F., Brasfield, F., Heaton, R., Glinsmann‐Gibson, B., Crook, L., Taetle, R., & Capizzi, R. L. (1997) · Blood · doi:10.1182/blood.v90.9.3364 · Cited by 123
Miller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1993) · Annals of Hematology · doi:10.1007/bf01697631 · Cited by 114
Miller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1992) · Annals of Hematology · doi:10.1007/bf01703109 · Cited by 113
Zagonel, V., Re, G. L., Marotta, G., Babare, R., Sardeo, G., Gattei, V., Angelis, V. D., Monfardini, S., & Pinto, A. (1993) · PubMed · Cited by 92
Willemze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P. A., Louwagie, E. A., Berneman, Z. N., T'Jean, M., Wijermans, P., Döhner, H., et al. (1997) · PubMed · Cited by 87
Self-citationCheson, B. D., & Simon, R. M. (1987) · PubMed · Cited by 68
Hh, G., Marcus, R. E., Delmer, A. J., Zwierzina, H., Suciu, S., Dardenne, M., Solbu, G., de Witte, T., Jacobs, A., & Visani, G. (1994) · PubMed · Cited by 55
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Metadata
- Authors
- Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-03-01
- Volume
- 18
- Issue
- 5
- Pages
- 956-956
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1879966002
- Cited by
- 567
- References
- 17
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.